Skip to main content

Table 4 Antimicrobial susceptibility of M. catarrhalis as classified by CLSI and EUCAST §

From: Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Antimicrobial agenta(n° of strains) CLSI susceptibility breakpoint (mg/L) EUCAST susceptibility breakpoint(mg/L) CLSI %S EUCAST %S Type of discrepancyb
Amoxicillin-clavulanate (3.549) 4 1 100 99.9 -
Cefaclor (7.536) 8 0.12 95.1 0.27 very major
Cefuroxime axetil (15.381) 4 0.125 98.7 1.2 very major
Cefotaxime (2.737) 2 1 99.9 99.6 -
Ceftriaxone (5.187) 2 1 99.9 99.1 -
Clarithromycin (910) 1 0.25 100 99.9 -
Erythromycin (3.038) 2 0.25 100 99.7 -
Ciprofloxacin (11.119) 1 0.5 99.9 99.9 -
Levofloxacin (5.239) 2 1 100 99.9 -
Tetracycline (8.660) 2 1 97.7 94.8 -
  1. § CLSI [11] and EUCAST [13].
  2. aFor Chloramphenicol and Trimethoprim/sulfamethoxazole CLSI and EUCAST suggested the same susceptibility breakpoints.
  3. b Discrepancy as defined in the materials and methods section.